2
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
2
Leukemia, Myeloid, Acute
2
Osteoarthritis
1
Lymphoma, B-Cell
1
Low Back Pain
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Cancer Pain
1
Interventions
Rituximab
313
Cyclophosphamide
286
fludarabine phosphate
213
fludarabine
140
ibrutinib
121
Peripheral Blood Stem Cell Transplantation
116
venetoclax
108
Mycophenolic Acid
102
obinutuzumab
88
Lenalidomide
88
Bendamustine Hydrochloride
87
Whole-Body Irradiation
85
Filgrastim
84
Tacrolimus
78
Cyclosporine
78
Busulfan
70
Melphalan
65
Radiotherapy
63
Antilymphocyte Serum
61
Alemtuzumab
58
Etoposide
56
acalabrutinib
54
Methotrexate
49
ofatumumab
46
idelalisib
38
Cytarabine
33
Chlorambucil
33
zanubrutinib
31
sargramostim
30
Specimen Handling
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
Inosine Monophosphate
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled